Reply to: “Thiazides and nonmelanoma skin cancer: Is it a class effect?” - 11/12/19
Doi : 10.1016/j.jaad.2019.09.004
Sidsel Arnspang Pedersen, MD, PhD a, b, ⁎ 
, Anton Pottegård, PhD b
, Anton Pottegård, PhD b a Department of Clinical Biochemistry and Clinical Pharmacology, Odense University Hospital, Denmark
b Department of Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense
∗Correspondence to: Sidsel Arnspang Pedersen, MD, PhD.
Abbreviations used : BCC, OR, SCC
Le texte complet de cet article est disponible en PDF.
| Funding sources: Supported by grants from the Danish Cancer Society (grant R72-A4417 to Dr Arnspang Pedersen) the Danish Council of Independent Research (grant 4004-00234B to Dr Pottegård). The funding sources had no role in the design of the study, data analysis, or interpretation of the results. |
|
| Disclosure: Dr Pottegård has participated in research projects unrelated to the present study and used grants provided by LEO Pharma (manufacturer of bendroflumethiazide) to the institution at which he was employed. Dr Arnspang Pedersen has no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 1
P. e27 - janvier 2020 Retour au numéro
Article précédent
- Thiazides and nonmelanoma skin cancer: Is it a class effect?
- Xavier Humbert, Charles Dolladille, Basile Chrétien, Marion Sassier, Sophie Fedrizzi, Paolo-Emilio Puddu, Joachim Alexandre
- Comment on “Platelet-rich plasma and its utility in the treatment of acne scars: A systematic review”
- I-Hsin Huang, Yu-Chen Huang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?